// App-Quantinova.ai

P4-01-01 : Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial

Researchers

Presenter

  • Liu MC

Principal Investigators

  • Dueck AC

  • Janni W

  • Wolff AC

  • Harris LN

  • Gralow JR

  • Pritchard KI

  • Ellard S

  • Le-Lindqwister NA

  • Boyle F

  • de Azambuja E

  • Piccart-Gebhart MJ

  • Hillman DW

  • Ignatiadis M

  • Perez EACampion MB

  • Reinholz MM

  • Halling KC

  • Sotiriou C

  • Rothe F

  • Maetens M

  • Rouas G

Medical Centers

  • Seattle Cancer Care Alliance, Seattle, WA

  • Institute Jules Bordet, Brussels, Belgium

  • Illinois CancerCare PC, Peoria, IL

  • Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Mayo Clinic, Rochester, MN

  • Johns Hopkins Hpsital/Sidney Kimmel Comprehensive Cancer Center, Baltimore, MDMayo Clinic, Jacksonville, FLVentana Medical Systems, Inc, A Memberof the Roche Group, Tuscon, AZ

  • Case Western/Seidman Cancer Center, Cleveland, OH

  • Mayo Clinic, Scottsdale, AZ

  • British Columbia Cancer Agency, Southern Interior Centre, Kelowna, BC, Canada

  • Ludwig Maximilians University Munich, Munich, Germany

  • Universitaetsfrauenklinik, Ulm, Germany

  • Patricia Ritchie Centre for Cancer Care and Research, University of Sydney, Mater Hospital, North Sydney, Australia

Locations

  • Canada

  • Germany

  • Australia

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • Lapatinib

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Roche

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved